In this episode, we'll hear the evolution of the advanced practitioners (APs) role at an institution, where APs have a larger voice in the research process and clinical trial protocols, and collaborate in clinical trial delivery.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts!
While most cancer programs in the United States report that they employ advanced practitioners (APs), they are often not utilized to the full scope of their abilities in clinical research.
In this episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, shares the evolution of the advanced practitioner role at her institution, where APs have a larger voice in the research process and clinical trial protocols, serve as champions to advocate for patients and research staff, and collaborate with their team to promote best practices in clinical trial delivery.
“I started advocating for myself and my advanced practitioner colleagues to have a larger voice in clinical trial participation. By increasing our knowledge so we know about the research studies coming in, and working together as a team with physician champions, it’s been a group effort."
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN
Nurse Practitioner
Cleveland Clinic
Cleveland, Ohio
This mini-podcast—in addition to Episodes 60 and 63—will share key themes from the Summit discussions.
Thank you to Pfizer Oncology for their collaboration and support in hosting the ACCC-Harborside Virtual Summit.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
